Histone deacetylase inhibitor tributyrin and vitamin A in cancer

1Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Bioactive food compounds like vitamin A and the butyrate's prodrug tributyrin have preventive activities against different types of cancer, and their use in association could represent a promising strategy for cancer treatment and chemoprevention. Both compounds can induce cell differentiation and apoptosis of neoplastic and preneoplastic cells by means of modulation of gene transcription, yet they act through different but interconnected mechanisms. Vitamin A acts through nuclear receptors that are tightly regulated by histone modifications such as acetylation and DNA methylation. Tributyrin modulates transcription of genes by HDACs inhibition and histone hyperacetylation. This chapter describes how epigenetics mediates the antineoplastic and chemopreventive activity of vitamin A, tributyrin, and their derivatives and how their combination can be used to help overcome current limitations in cancer treatment and prevention. We also show how the mechanisms of action of vitamin A and tributyrin have aided in the development of synthetic and bioengineered compounds like synthetic retinoids and structured lipids, respectively.

Cite

CITATION STYLE

APA

Heidor, R., Vargas-Mendez, E., & Moreno, F. S. (2019). Histone deacetylase inhibitor tributyrin and vitamin A in cancer. In Handbook of Nutrition, Diet, and Epigenetics (Vol. 3, pp. 1615–1636). Springer International Publishing. https://doi.org/10.1007/978-3-319-55530-0_72

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free